Management of the newborn infant affected by maternal opiates and other drugs of dependency

Journal of Paediatrics and Child Health

Volumn 43, Issue 1-2, 2007, Pages 9-18

  Oei, Julee ^b   Lui, Kei ^a  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b NONE

Author keywords

Illicit drug; Neonatal abstinence syndrome; Opiate; Pregnancy

Indexed keywords

ALCOHOL; AMPHETAMINE; ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; CANNABIS; CLONIDINE; COCAINE; DIAMORPHINE; DIAZEPAM; ILLICIT DRUG; METHADONE; MORPHINE; NARCOTIC AGENT; NICOTINE; OPIATE; PAREGORIC; PHENOBARBITAL; SEDATIVE AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

BREATHING; CARDIOPULMONARY INSUFFICIENCY; CHILD; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG SCREENING; HAIR ANALYSIS; HIGH RISK INFANT; HUMAN; HYPOTENSION; LENGTH OF STAY; LOADING DRUG DOSE; METHADONE TREATMENT; MONOTHERAPY; NEWBORN MONITORING; NONHUMAN; OPIATE ADDICTION; PREGNANCY; PRENATAL DEVELOPMENT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; RATING SCALE; REVIEW; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SUCKING; TOXICITY TESTING; WITHDRAWAL SYNDROME;

FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; NEONATAL NURSING; OPIOID-RELATED DISORDERS; PREGNANCY;

EID: 33845724649     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2007.00994.x     Document Type: Review

References (126)

1. Department of Health Statistical Bulletin 1997. London: HMSO, 1997.
2. Australian Institute of Health and Welfare 2005. 2004 National Drug Strategy Household Survey: First Results. AIHW cat. No. PHE 57, Canberra; AIHW (Drug Statistics Series No. 13). Available from http://www.aihw.gov.au [accessed 5 April 2005].
3. Leung K, Kluckow M, Lui K for the Neonatal Abstinence Working Group, NSW Pregnancy and Newborn Services Network. Chemical use in pregnancy - a NSW statewide survey of birthing hospitals. Proceedings of the 6th Annual Congress of the Perinatal Society of Australia and New Zealand; 9-13 March 2002, Christchurch, New Zealand.
4. Craig F, Oei J, Kent-Biggs J, Lui K. Drug dependency in pregnancy - a statewide survey of maternity hospitals in NSW. Proceedings of the 9th Annual Congress of the Perinatal Society of Australia and New Zealand; 13-16 March 2005, Adelaide, South Australia.
5. Abdel-Latif ME, Bajuk B, Lui K, Oei J and the NSW & ACT NICUS Group. The short-term outcomes of infants of substance-using mothers admitted to neonatal intensive care units in NSW and the ACT. J Paediatr Child Health (in press).
6. Kennare R, Heard A, Chan A. Substance use during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. ANZJOG 2005; 45: 220-5.
7. Morrison C, Siney C. Maternity services for drug misusers in England and Wales: a national survey. Health Trends 1995; 27: 1.
8. Vega WA, Kolody B, Hwang J et al. Perinatal drug use among immigrant and native-born Latinas. Subst. Use Misuse 1997; 32: 43-62.
9. El-Mohandes A, Herman AA, Nabil El-Khorazaty M et al. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J. Perinatol. 2003; 23: 354-60.
10. Khalsa JH, Gfroerer J. Epidemiology and health consequences of drug abuse among pregnant women. Semin. Perinatol. 1991; 15: 265-70.
11. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet. Gynecol. 2003; 101: 374-9.
12. Inthawiwat S, Rattanachaiyanont M, Leerasiri P et al. Increasing trend of illicit drug abuse in Thai parturient at Siriraj Hospital. J. Med. Assoc. Thai. 2002; 85: 1081-8.
13. Coleman PK, Reardon DC, Rue WM, Cougle J. A history of induced abortion in relation to substance use during subsequent pregnancies carried to term. Am. J. Obstet. Gynecol. 2002; 187: 1673-8.
14. National Pregnancy and Health Survey. Table 4-2. In: Estimated Percentage and Numbers (in Thousands) of Infants Exposed Prenatally to Selected Substances: United States. NIH Publication No. 96-3819. Rochulle, MO: National Institute on Drug Abuse, 1996; 37.
15. Arlettaz R, Kashiwagi M, Das-Kendu S et al. Methadone maintenance program in pregnancy in a Swiss perinatal Centre (II): neonatal outcome and social resources. Acta Obstet. Gynecol. Scand. 2005; 84: 145-50.
16. Manfredi LG, Rocchi R, Panerai A et al. EEG sleep patterns and endogenous opioids in infants of narcotic-addicted mothers. Rev. Electroencephalogr. Neurophysiol. Clin. 1983; 13: 199-206.
17. Pinto F, Torrioli MG, Casella G et al. Sleep in babies born to chronically heroin addicted mothers: a follow up study. Drug Alcohol Depend. 1988; 21: 43-7.
18. Van Baar AL, Fleury P, Soepatmi S et al. Neonatal behaviour after drug dependent pregnancy. Arch. Dis. Child. 1989; 64: 235-40.
19. Herzlinger RA, Kandall SR, Vaughan HG. Neonatal seizures associated with narcotic withdrawal. J. Pediatr. 1971; 91: 638-41.
20. Zelson C, Rubio E, Wasserman E. Neonatal narcotic addiction: 10 year observation. Pediatrics 1971; 48: 178-89.
21. Kandall SR, Gartner LM. Late presentation of drug withdrawal symptoms in newborns. Am. J. Dis. Child. 1974; 127: 58-61.
22. Bleyer WA, Marshall RE. Barbiturate withdrawal syndrome in a passively addicted infant. JAMA 1972; 221: 185-6.
23. Feld LH, Negus JB, White PF. Oral midazolam preanesthetic medication in pediatric outpatients. Anesthesiology 1990; 73: 831-4.
24. Pierog S, Chandavasu O, Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J. Pediatr. 1977; 90: 630-3.
25. Kron RE, Litt M, Phoenix MD, Finnegan LP. Neonatal narcotic abstinence: effects of pharmacotherapeutic agents and maternal drug usage on nutritive sucking behavior. J. Pediatr. 1976; 88: 637-41.
26. Martinez A, Kastner B, Taeusch HW. Hyperphagia in neonates withdrawing from methadone. Arch. Dis. Child. Fetal Neonatal Ed. 1999; 80: F178-82.
27. Shephard R, Greenough A, Johnson K, Gerada C. Hyperphagia, weight gain and neonatal drug withdrawal. Acta Paediatr. 2002; 91: 951-3.
28. Finnegan LP, Connaughton JF Jr, Kron RE et al. Neonatal abstinence syndrome: assessment and management. Addict. Dis. 1975; 2: 141-58.
29. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin. Pediatr. (Phila) 1975; 14: 592-4.
30. Green M, Suffret F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. Am. J. Drug Alcohol Abuse 1981; 8: 203-13.
31. Zahorodny W, Rom C, Whitney W et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J. Dev. Behav. Pediatr. 1998; 19: 89-93.
32. Pakalapati R, Bolisetty S, Austin MP, Oei J. Neonatal seizures from inutero venlafaxine. J. Paediatr. Child Health 2006; 42: 737-8.
33. Chasnoff IJ, Burns WJ. The Moro reaction: a scoring system for neonatal narcotic withdrawal. Dev. Med. Child Neurol. 1984; 26: 484-9.
34. O'Brien C, Hunt R, Jeffery HE. Measurement of movement is an objective method to assist in assessment of opiate withdrawal in newborns. Arch. Dis. Child. Fetal Neonatal Ed. 2004; 89: F305-9.
35. Oro AS, Dixon SD. Perinatal cocaine and metamphetamine exposure. Maternal and neonatal correlates. J. Pediatr. 1987; 111: 571-8.
36. Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and metamphetamine use: incidence and clinical correlates. J. Pediatr. 1989; 115: 770-8.
37. Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust. N. Z. J. Obstet. Gynecol. 1987; 27: 92-8.
38. Bartu AE, Doherty DA, Francis JA. Incidence and correlates of NAS in infants exposed to methadone, amphetamine type substances and other drugs. P9, 9th Annual congress of the Perinatal Society of Australia and New Zealand; 13-16 March 2005, Adelaide, South Australia.
39. Fulroth R, Phillips B, Durand J. Perinatal outcome of infants exposed to cocaine and/or heroin in utero. Am. J. Dis. Child. 1989; 143: 205-10.
40. Schindler DS, Eder H, Ortner R. et al. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003; 98: 103-10.
41. Kayemba-Kay's S, Laclyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 2003; 98: 1599-604.
42. Lacroix I, Berrebi A, Chaumerliac C et al. Buprenorphine in pregnant opioi-dependent women: first results of a prospective study. Addiction 2004; 99: 209-14.
43. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S, Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend. 2006; 82: 250-7. Epub 2005 Oct 27.
44. Iqbal MM, Sobhan T, Ryais T. Effects of commonly used benzodiazepines on the fetus, the neonate and the nursing infant. Psychiatr. Serv. 2002; 53: 39-49.
45. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome amongst infants of drug dependant mothers. Pediatrics 2006; 117: e1163-9.
46. Heishman SJ. Nicotine: pharmacology and addiction. Am. Assoc. Clin. Chem. 1999; 20: 227-38.
47. Law KL, Stroud LR, LaGasse LL et al. Smoking during pregnancy and newborn behaviour. Pediatrics 2003; 111 (6 pt 1): 1318-23.
48. Choo RE, Huestis MA, Schroeder JR et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 2004; 75: 253-60.
49. Ostrea E, Chavez C, Strauss M. A study of factors that influence the severity of neonatal narcotic withdrawal. J. Pediatr. 1976; 88: 642-5.
50. Madden JD, Chappel JN, Zuspan F et al. Observation and treatment of neonatal narcotic withdrawal. Am. J. Obstet. Gynecol. 1977; 127: 199-201.
51. Harper R, Solish G, Feingold E et al. Maternal ingested methadone, body fluid methadone and the neonatal withdrawal syndrome. Am. J. Obstet. Gynecol. 1977; 129: 417-24.
52. Kandall SR, Doberczak TM, Mauer KR et al. Opiate v CNS depressant therapy in neonatal drug abstinence syndrome. Am. J. Dis. Child. 1983; 137: 378-82.
53. Suffet F, Brotman R. A comprehensive care program for pregnant addicts: obstetrical, neonatal and child development outcomes. Intern. J. Addict. 1984; 19: 199-219.
54. Offidani C, Chiarotti M, DeGiovanni N, Falasconi AM. Methadone in pregnancy: clinical, toxicological aspects. J. Clin. Toxicol. 1986; 24: 295-303.
55. Malpas TJ, Darlow BA, Lennox R, Horwood LJ. Maternal methadone dosage and neonatal withdrawal. Aust. N. Z. J. Obstet. Gynecol. 1995; 35: 175-7.
56. Mayes LC, Carroll KM. Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. Subst. Use Misuse 1996; 31: 241-53.
57. Dashe JS, Sheffield JS, Olscher DA et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet. Gycecol. 2002; 100: 1244-9.
58. Mack G, Thomas D, Giles W, Buchanan N. Methadone levels and neonatal withdrawal. J. Pediatr. Child Health 1991; 27: 96-100.
59. Shaw NJ, McIvor L. Neonatal abstinence syndrome after maternal methadone treatment. Arch. Dis. Child. 1994; 71: F203-5.
60. Hagopian GS, Wolfe HM, Sokol RJ et al. Neonatal outcome following methadone exposure in utero. J. Matern. Fetal Med. 1996; 5: 348-54.
61. Brown HL, Briton KA, Mahaffey D et al. Methadone maintenance in pregnancy: a reappraisal. Am. J. Obstet. Gynecol. 1998; 179: 459-63.
62. Berghella V, Lim PJ, Hill MK et al. Maternal methadone dose and neonatal withdrawal. Obstet. Gynecol. 2003; 101 (5 Pt 2): 1060-2.
63. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J. Addict. Dis. 1999; 18: 51-61.
64. Drozdick J 3rd, Berghella V, Hill M, Kaltenback K. Methadone trough levels in pregnancy. Am. J. Obstet. Gynecol. 2002; 197: 1184-8.
65. Jackson L, Ting A, McKay S et al. A randomized controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 2004; 89: F300-F304.
66. Smith J, Yonekura ML, Wallace T et al. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J. Dev. Behav. Pediatr. 2003; 24: 17-23.
67. Zelson C, Rubio E, Wasserman E. Neonatal narcotic addiction: 10 year observation. Pediatrics 1971; 48: 178-89.
68. Desmond MM, Wilson GS. Neonatal abstinence syndrome: recognition and diagnosis. Addict. Dis. 1975; 2: 113-21.
69. Steg N. Narcotic withdrawal reactions in the newborn. Am. J. Dis. Child. 1957; 94: 286-8.
70. Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdawal syndrome. J. Pediatr. 1976; 88: 1044-8.
71. Doberczak T, Kandall S, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J. Pediatr. 1991; 118: 933-7.
72. Doberczak TM, Kandall SR, Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels and neonatal withdrawal. Obstet. Gynecol. 1993; 81: 936-40.
73. Kuschel CA, Austeberry L, Cornwell M et al. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch. Dis. Child. Fetal Neonatal Ed. 2004; 89: F390-F393.
74. Jain L, Meyer W, Moore C et al. Detection of fetal cocaine exposure by analysis of amniotic fluid. Obstet. Gynecol. 1993; 81 (5 Pt 1): 787-90.
75. Kim E, Brion LP, Meenan G et al. Perinatal toxicology screening: comparison of various maternal and neonatal samples. J. Perinatol. 1998; 18: 116-21.
76. Skopp G, Potsch L. A case report on drug screening of nail clippings to detect prenatal drug exposure. Ther. Drug Monit. 1997; 19: 386-9.
77. Ostrea EM Jr, Knapp DK, Tannenbaum L et al. Estimates of iillicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J. Pediatr. 2001; 138: 344-8.
78. Vinner E, Vignau J, Thibault D et al. Hair analysis of opiates in mothers and newborns for evaluating opiate exposure during pregnancy. Forensic Sci. Int. 2003; 133 (1-2): 57-62.
79. Ostrea EM Jr, Brady M, Gause S et al. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics 1992; 89: 107-13.
80. Wingert WE, Feldman MS, Kim MH et al. A comparison of meconium, maternal urine and neonatal urine for detection of maternal drug use during pregnancy. J. Forensic Sci. 1994; 39: 150-8.
81. Maichuk GT, Zahorodny W, Marshall R. Use of positioning to reduce the severity of neonatal narcotic withdrawal syndrome. J. Perinatol. 1999; 19: 510-3.
82. Oro AS, Dixon SD. Waterbed care of narcotic-exposed neonates. A useful adjunct to supportive care. Am. J. Dis. Child. 1988; 142: 186-8.
83. D'Apolito K. Comparison of a rocking bed and standard bed for decreasing withdrawal symptoms in drug-exposed infants. MCN Am. J. Matern. Child Nurs. 1999; 24: 138-44.
84. Carin I, Glass L, Parekh A et al. Neonatal methadone withdrawal: effect of two treatment regimens. Am. J. Dis. Child. 1983; 137: 1166-9.
85. Kaltenbach K, Finnegan LP. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav. Toxicol. Teratol. 1986; 8: 353-5.
86. Kolb J, Himmelsbach CK. Clinical studies of drug addiction: critical review of withdrawal treatment with method of evaluating abstinence syndrome. Am. J. Psychiatry 1983; 94: 759.
87. Pacifico P, Nardelli E, Pantarotto MF. Neonatal heroin withdrawal syndrome: evaluation of different pharmacological treatments. Pharmacol. Res. 1989; 21 (Suppl. 1): 63-4.
88. Lainwala S, Brown ER, Weinschenk NP et al. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv. Neonatal Care 2005; 5: 265-72.
89. Guo J, Greenberg M, Finer NN, Heldt GP. Methadone is a superior detoxification agent compared to tincture opium for treatment of neonatal narcotic abstinence syndrome (NAS). Proceedings of the 2006 Pediatric Academic Societies Meeting; 29 April-2 May 2006, San Francisco, California, USA.
90. Langenfeld S, Birkenfeld L, Herkenrath P et al. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend. 2005; 77: 31-6.
91. Coyle MG, Ferguson A, Lagasse L et al. Diluted tincture of opium (DTO) and Phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J. Pediatr. 2002; 140: 561-4.
92. Raol YH, Zhang G, Budreck EC, Brooks-Kayal AR. Long-term effects of diazepam and Phenobarbital treatment during development on GABA receptors, transports and glutamic acid decarboxylase. Neuroscience 2005; 132: 399-407.
93. Little PJ, Price RR, Hinton RK, Kuhn CM. Role of noradrenergic hyperactivity in neonatal opiate abstinence. Drug Alcohol Depend. 1996; 41: 47-54.
94. Klamt JG, Garcia LV, Stocche RM et al. Epidural infusion of clonidine or clonidine plus ropivacaine for postoperative analgesia in children undergoing major abdominal surgery. J. Clin. Anesth. 2003; 15: 510-4.
95. Deutsch ES, Nadkarni VM. Clonidine prophylaxis for narcotic and sedative withdrawal syndrome following laryngotracheal reconstruction. Arch. Otolaryngol. Head Neck Surg. 1996; 122: 1234-8.
96. Constant I, Gall O, Gouyet L et al. Addition of clonidine or fentanyl to local anaesthetics prolongs the duration of surgical analgesia after single shot caudal block in children. Br. J. Anaesth. 1998; 80: 294-8.
97. Ambrose C, Sale S, Howells R. et al. Intravenous clonidine infusion in critically ill children: dose-dependent sedative effects and cardiovascular stability. Br. J. Anaesth. 2000; 84: 794-6.
98. Hoder EL, Leckman JF, Poulsen J et al. Clonidine treatment of neonatal narcotic abstinence syndrome. Psychiatry Res. 1984; 13: 243-51.
99. Autret F, Mucignat V, De Montgolfier-Aubron I et al. Use of diazepam in the treatment of opioid neonatal abstinence syndrome. Arch. Pediatr. 2004; 11: 1308-13.
100. Chapman JP, Galea P. Neonatal abstinence syndrome at Glasgow Royal maternity hospital. Health Bull. (Edinb) 1999; 57: 247-51.
101. Oei J, Feller JM, Lui K. Coordinated outpatient care of the narcotic-dependent infant. J. Paediatr. Child Health 2001; 37: 266-70.
102. Coghlan D, Milner M, Clarke T et al. Neonatal abstinence syndrome. Ir. Med. J. 1999; 92: 232-3, 236.
103. Intergovernmental Committee on Drugs.National Clinical Guidelines for the Management of Drug Use During Pregnancy, Birth and the Early Development Years of the Newborn, 2006. Available from: http://www.health.nsw.gov.au [accessed 1 March 2006].
104. Ballard JL. Treatment of neonatal abstinence syndrome with breast milk containing methadone. J. Perinat. Neonatal Nurs. 2002; 15: 76-85.
105. Begg EJ, Malpas TJ, Hackett LP et al. Distribution of R- and Smethadone into human milk during multiple, medium and high oral dosing. Br. J. Clin. Pharmacol. 2001; 52: 681-5.
106. Wojnar-Horton RE, Kristensen JH, Yapp P et al. Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br. J. Clin. Pharmacol. 1997; 44: 543-7.
107. Malpas TJ, Darlow BA. Neonatal abstinence syndrome following abrupt cessation of breastfeeding. N. Z. Med. J. 1999; 112: 12-3.
108. Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of literature and current management guidelines. J. Hum. Lac. 2004; 20: 62-71.
109. Bada HS, Das A, Bauer CR et al. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet. Gynecol. 2002; 100 (5 Pt 1): 916-24.
110. Ogunyemi D, Hernandez-Loera G. The impact of antenatal cocaine use on maternal characteristics and neonatal outcomes. J. Matern. Fetal Neonatal Med. 2004; 15: 253-9.
111. Olsen GD, Lees MH. Ventilatory response to carbon dioxide of infants following chronic prenatal methadone exposure. J. Pediatr. 1980; 96: 983-9.
112. Gill AC, Oei J, Lewis NL et al. Strabismus in infants of opiate-dependent mothers. Acta Paediatr. 2003; 92: 379-8.
113. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2005; 40: 458-65. Epub 2005 Jan 7.
114. Coutsoudis A. Infant feeding dilemmas created by HIV: South African experiences. J. Nutr. 2005; 135: 956-9.
115. Mast EE. Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv. Exp. Med. Biol. 2004; 554: 211-6.
116. Plunkett BA, Grobman WA. Elective cesarean delivery to prevent perinatal transmission of hepatitis C virus: a cost-effectiveness analysis. Am. J. Obstet. Gynecol. 2004; 191: 998-1003.
117. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36 (5 Suppl. 1): S106-13.
118. Hans SL. Demographic and psychosocial characteristics of substance-abusing pregnant women. Clin. Perinatol. 1999; 26: 55-74.
119. Martin SL, Beaumont JL, Kupper LL. Substance use before and during pregnancy: links to intimate partner violence. Am. J. Drug Alcohol Abuse 2003; 29: 599-617.
120. Jaudes PK, Ekwo E, Van Voorhis J. Association of drug abuse and child abuse. Child Abuse Negl. 1995; 19: 1065-75.
121. Howell EM, Heiser N, Harrington M. A review of recent findings on substance abuse treatment for pregnant women. J. Subst. Abuse Treat. 1999; 16: 195-219.
122. Ho E, Karimi-Tabesh L, Koren G. Characteristics of pregnant women who use ecstasy (3,4-methylenedioxymetamphetamine). Neurotoxicol. Teratol. 2001; 23: 561-7.
123. Barnet B, Duggan AK, Wilson MD, Joffe A. Association between postpartum substance use and depressive symptoms, stress, and social support in adolescent mothers. Pediatrics 1995; 96: 659-66.
124. Singer L, Arendt R, Minnes S et al. Increased psychological distress in post-partum, cocaine-using mothers. J. Subst. Abuse 1995; 7: 165-74.
125. Soepatmi S. Developmental outcomes of children of mothers dependent on heroin or heroin/methadone during pregnancy. Acta Paediatr. Suppl. 1994; 404: 36-9.
126. Lawford BR, Young RM, Noble EP et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am. J. Med. Genet. 2000; 96: 592-8.